New Jersey Governor's School in the Sciences to Tackle Human Memory
Students Benefit from NJGSS Bayer HealthCare Program in Neuroscience
MADISON, N.J., July 28, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals is pleased to sponsor a newly expanded curriculum developed and facilitated by Drew science faculty at this summer's New Jersey Governor's School in the Sciences (NJGSS) at Drew University. The program will enable the state's most academically talented high school juniors to interact face-to-face in the classroom and laboratory with Alzheimer's disease, human memory and other topics in neuroscience.
"Neuroscience becomes especially important when nervous systems misbehave," said Dr. David Miyamoto, a biologist and director of the NJGSS. "Such misbehaviors show up in humans as pathological conditions like Alzheimer's, autism, epilepsy and other neurological diseases. Understanding the basis of these conditions offers the hope that we can alleviate or even cure them."
The newly enhanced neuroscience component of the NJGSS comes in two parts: an academic course and laboratory investigations. The course, which will focus on diseases of the brain and the biological basis for human memory, will be taught by Dr. Roger Knowles, a leading Alzheimer's researcher and associate professor of biology and neuroscience at Drew. In the lab, one group of students will work with Dr. Graham Cousens, assistant professor psychology, on olfactory learning and memory. The remaining students will join Dr. Minjoon Kouh, assistant professor of physics, in using computer modeling to research how the brain processes information.
The NJGSS, which is running from July 10 to 30, also offers courses in cell biology, physics, mathematics, anthropology and chemistry. The summer program has received generous financial support from Bayer HealthCare Pharmaceuticals for the last three years.
"As a company dedicated to science, we are committed to supporting important programs like the NJGSS," said Sandra J. Oliver, Vice President, Public Policy and Government Affairs at Bayer. Located in Wayne, the company's aim is to develop and manufacture products that will improve human health by diagnosing, preventing and treating diseases.
Bayer HeathCare Pharmaceuticals' generous support of the NJGSS is part of its Making Science Make Sense® (MSMS) initiative, which advances science literacy through hands-on, inquiry-based science education, employee volunteerism and a public education campaign. Currently, 12 Bayer sites around the country operate local MSMS programs, which together represent a national volunteer corps of more than 1,000 employees.
About Drew University -- Founded in 1867, Drew is a selective, independent, coeducational university with a total enrollment of more than 2,700 students in its College of Liberal Arts, Caspersen School of Graduate Studies and Theological School. Widely recognized for academic excellence and its tight-knit, diverse community, Drew is routinely listed among the nation's top colleges by The Princeton Review. Having won Rhodes, Fulbright, Truman, Goldwater, Marshall and National Science Foundation scholarships, Drew students are among the best in the nation. The university is one of three in New Jersey with a chapter of Phi Beta Kappa, the nation's most prestigious academic honor society.
About Bayer HealthCare Pharmaceuticals Inc. -- Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.
SOURCE Bayer HealthCare Pharmaceuticals
More by this Source
Bayer to Present Data Investigating Recently Approved Adempas® (riociguat) Tablets
Oct 28, 2013, 09:51 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.